GRAL Logo

GRAIL, Inc. (GRAL) Stock Forecast & Price Prediction

Live GRAL Stock Price & Analysis

Home โ€บ Stocks โ€บ United States | NASDAQ | Healthcare | Diagnostics & Research

$33.37

+1.16 (3.60%)

12 Month Price Forecast For GRAL

$33.37
Current Price
$1.08B
Market Cap
3 Ratings
Buy 0
Hold 3
Sell 0
Wall St Analyst Ratings

Distance to GRAL Price Forecasts

-52.1%
To High Target of $16.00
-56.5%
To Median Target of $14.50
-61.0%
To Low Target of $13.00

GRAL Price Momentum

+18.0%
1 Week Change
+88.2%
1 Month Change
0.0%
1 Year Change
+86.9%
Year-to-Date Change
-6.4%
From 52W High of $35.67
+170.6%
From 52W Low of $12.33

๐Ÿค” Considering GRAIL (GRAL)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 11, 2025 8:26 AM UTC

GRAL Analyst Ratings & Price Targets

Based on our analysis of 2 Wall Street analysts, GRAL has a neutral consensus with a median price target of $14.50 (ranging from $13.00 to $16.00). Currently trading at $33.37, the median forecast implies a -56.5% downside. This outlook is supported by 0 Buy, 3 Hold, and 0 Sell ratings.

The most optimistic forecast comes from Tejas Savant at Morgan Stanley, projecting a 52.1% downside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

GRAL Analyst Consensus

0
Buy
3
Hold
0
Sell

GRAL Price Target Range

Low
$13.00
Average
$14.50
High
$16.00
Current: $33.37

Latest GRAL Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for GRAL.

Date Firm Analyst Rating Change Price Target
Nov 27, 2024 Morgan Stanley Tejas Savant Equal-Weight Initiates $16.00
Oct 17, 2024 Guggenheim Subbu Nambi Neutral Initiates $0.00

Stocks Similar to GRAIL, Inc.

The following stocks are similar to GRAIL based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

GRAIL, Inc. (GRAL) Financial Data

GRAIL, Inc. has a market capitalization of $1.08B with a P/E ratio of -0.8x. The company generates $117.67M in trailing twelve-month revenue with a -102.7% profit margin.

Revenue growth is +38.3% quarter-over-quarter, while maintaining an operating margin of -640.5% and return on equity of -35.2%.

Valuation Metrics

Market Cap $1.08B
Enterprise Value $288.13M
P/E Ratio -0.8x
PEG Ratio 0.0x
Price/Sales 9.2x

Growth & Margins

Revenue Growth (YoY) +38.3%
Gross Margin -77.6%
Operating Margin -640.5%
Net Margin -102.7%
EPS Growth N/A

Financial Health

Cash/Price Ratio +77.0%
Current Ratio 9.7x
Debt/Equity 2.8x
ROE -35.2%
ROA -32.8%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

GRAIL, Inc. logo

GRAIL, Inc. (GRAL) Company Overview

About GRAIL, Inc.

What They Do

Develops technologies for early cancer detection.

Business Model

The company generates revenue through its innovative screening and diagnostic tests, including Galleri for asymptomatic individuals and DAC as a diagnostic aid. By focusing on early detection, GRAIL aims to improve patient outcomes while also addressing a significant market need for accurate and timely cancer diagnostics.

Additional Information

Founded in 2015 and based in Menlo Park, California, GRAIL, Inc. was previously a subsidiary of Illumina, Inc. The company is actively engaged in developing additional tests for minimal residual disease and other post-diagnostic applications, positioning itself as a leader in early cancer detection technologies.

Company Information

Sector

Healthcare

Industry

Diagnostics & Research

Employees

1,360

CEO

Mr. Robert P. Ragusa

Country

United States

IPO Year

2024

Website

grail.com

GRAIL, Inc. (GRAL) Latest News & Analysis

GRAL stock latest news image
Quick Summary

Grail (GRAL) shares hit a new record high, reflecting strong gains due to positive sentiment surrounding its early-detection cancer screening blood tests.

Why It Matters

Grail's record-high share price reflects strong market confidence in its innovative cancer screening technology, potentially driving future growth and investment interest.

Source: Investopedia
Market Sentiment: Positive
GRAL stock latest news image
Quick Summary

Grail, Inc. (GRAL) shares rose 20% intraday on Wednesday, making it the top gainer in the Nasdaq 100, surpassing Arm Holdings (ARM) and Netflix (NFLX).

Why It Matters

Grail, Inc.'s 20% share surge signals strong market interest and potential growth, indicating investor confidence and shifting focus within the Nasdaq 100, impacting overall market dynamics.

Source: Investopedia
Market Sentiment: Positive
GRAL stock latest news image
Quick Summary

GRAIL, Inc. reported minimal patient distress from multi-cancer early detection testing in the PATHFINDER study, with findings published in Lancet Oncology.

Why It Matters

Positive patient-reported outcomes from GRAIL's PATHFINDER study could enhance the company's credibility and market potential, influencing its stock performance in the healthcare sector.

Source: PRNewsWire
Market Sentiment: Neutral
GRAL stock latest news image
Quick Summary

GRAIL, Inc. (Nasdaq: GRAL) will present at the 43rd Annual J.P. Morgan Healthcare Conference, focusing on early cancer detection.

Why It Matters

GRAIL's presentation at a major conference highlights its potential for breakthroughs in cancer detection, influencing investor confidence and stock performance in the healthcare sector.

Source: PRNewsWire
Market Sentiment: Neutral
GRAL stock latest news image
Quick Summary

GRAIL (NASDAQ: GRAL) shares have increased by 58% since October 24, demonstrating strong performance over the past month and a half.

Why It Matters

GRAIL's 58% share price increase indicates strong market momentum, potentially signaling investor confidence and future growth prospects in the biotech sector.

Source: MarketBeat
Market Sentiment: Positive
GRAL stock latest news image
Quick Summary

Garmin and Ollie's Bargain Outlet are highlighted as top stocks to watch today, according to Investor's Business Daily's market analysis.

Why It Matters

Garmin and Ollie's Bargain Outlet are identified as market leaders, indicating potential growth and investment opportunities, which could influence stock performance and investor interest.

Source: Investors Business Daily
Market Sentiment: Positive

Frequently Asked Questions About GRAL Stock

What is GRAIL, Inc.'s (GRAL) stock forecast for 2025?

Based on our analysis of 2 Wall Street analysts, GRAIL, Inc. (GRAL) has a median price target of $14.50. The highest price target is $16.00 and the lowest is $13.00.

Is GRAL stock a good investment in 2025?

According to current analyst ratings, GRAL has 0 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $33.37. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for GRAL stock?

Wall Street analysts predict GRAL stock could reach $14.50 in the next 12 months. This represents a -56.5% decrease from the current price of $33.37. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is GRAIL, Inc.'s business model?

The company generates revenue through its innovative screening and diagnostic tests, including Galleri for asymptomatic individuals and DAC as a diagnostic aid. By focusing on early detection, GRAIL aims to improve patient outcomes while also addressing a significant market need for accurate and timely cancer diagnostics.

What is the highest forecasted price for GRAL GRAIL, Inc.?

The highest price target for GRAL is $16.00 from Tejas Savant at Morgan Stanley, which represents a -52.1% decrease from the current price of $33.37.

What is the lowest forecasted price for GRAL GRAIL, Inc.?

The lowest price target for GRAL is $13.00 from at , which represents a -61.0% decrease from the current price of $33.37.

What is the overall GRAL consensus from analysts for GRAIL, Inc.?

The overall analyst consensus for GRAL is neutral. Out of 2 Wall Street analysts, 0 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $14.50.

How accurate are GRAL stock price projections?

Stock price projections, including those for GRAIL, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.